Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	6.17	18.14	39.02	10.99	6.91
Revenue Growth (YoY)	-65.98%	-53.51%	255.11%	58.92%	15.02%
Cost of Revenue	54.04	73.7	84.41	65.5	49.34
Gross Profit	-47.87	-55.56	-45.39	-54.51	-42.42
Selling, General & Admin	25.83	22.48	17.83	17.14	14.85
Operating Expenses	25.83	22.48	17.83	17.14	14.85
Operating Income	-73.69	-78.03	-63.22	-71.65	-57.27
Interest Expense	-0.14	-0.46	-1.73	-2.86	-4.01
Interest & Investment Income	6.59	5.69	2.19	0.13	0.74
Earnings From Equity Investments	-	-	-	-	-2.55
Currency Exchange Gain (Loss)	-0.05	0.03	-0.02	0.01	-0.12
EBT Excluding Unusual Items	-67.3	-72.78	-62.78	-74.38	-63.21
Merger & Restructuring Charges	-	-	-	-	-0.06
Other Unusual Items	-2.63	-0.07	-2.23	-1.87	-0.47
Pretax Income	-69.92	-72.85	-65.01	-76.25	-63.75
Income Tax Expense	-	-	4.44	-	-
Net Income	-69.92	-72.85	-69.46	-76.25	-63.75
Preferred Dividends & Other Adjustments	-	-	-	12.14	12.12
Net Income to Common	-69.92	-72.85	-69.46	-88.39	-75.87
Shares Outstanding (Basic)	186	166	151	106	76
Shares Outstanding (Diluted)	186	166	151	106	76
Shares Change (YoY)	11.84%	9.95%	42.07%	40.10%	32.83%
EPS (Basic)	-0.38	-0.44	-0.46	-0.83	-1.00
EPS (Diluted)	-0.38	-0.44	-0.46	-0.83	-1.00
Free Cash Flow	-65.03	-86.94	-35.87	-68.34	-51.67
Free Cash Flow Per Share	-0.35	-0.52	-0.24	-0.64	-0.68
Gross Margin	-	-	-116.32%	-	-
Operating Margin	-1194.20%	-430.15%	-162.03%	-652.07%	-828.30%
Profit Margin	-1133.04%	-401.57%	-178.01%	-804.39%	-1097.31%
Free Cash Flow Margin	-1053.83%	-479.27%	-91.92%	-621.96%	-747.32%
EBITDA	-72.31	-76.63	-61.8	-69.9	-55.29
EBITDA Margin	-	-	-158.37%	-	-
D&A For EBITDA	1.38	1.4	1.43	1.75	1.98
EBIT	-73.69	-78.03	-63.22	-71.65	-57.27
EBIT Margin	-	-	-162.03%	-	-
Revenue as Reported	6.17	18.14	39.02	10.99	6.91

Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q